GoLUCK personal page - To The Moon

GoLUCK

GoLUCK

No personal profile

7Follow

4Followers

0Topic

0Badge

2021-08-19

Good

Analysts upbeat on Tilray's U.S. prospects after MedMen deal

2021-08-17

Yes

Sorry, the original content has been removed

2021-07-28

Nice

Sorry, the original content has been removed

2021-07-21

Yes

Sorry, the original content has been removed

2021-07-18

Nice

Sorry, the original content has been removed

2021-07-09

Nice

Sorry, the original content has been removed

2021-07-05

Nice

Neurodegenerative Disease, Cancer Stocks Among Top Biotech Gainers In 2021

2021-07-05

Like and comment

Is the Stock Market Open or Closed on Independence Day?

2021-07-04

Like pls

Can Alibaba Turn Around Its Woes in the Second Half of 2021?

2021-07-03

Wow

Sorry, the original content has been removed

2021-07-03

Like

Sorry, the original content has been removed

2021-06-23

Ok

Sorry, the original content has been removed

2021-06-23

Good

FDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3582022156707091","uuid":"3582022156707091","gmtCreate":1619156641859,"gmtModify":1619162108196,"name":"GoLUCK","pinyin":"goluck","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":7,"tweetSize":13,"questionSize":0,"limitLevel":999,"accountStatus":3,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.06.02","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":831205881,"gmtCreate":1629328295443,"gmtModify":1676530001835,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582022156707091","idStr":"3582022156707091"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/831205881","repostId":"2160379017","repostType":4,"repost":{"id":"2160379017","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1629300766,"share":"https://ttm.financial/m/news/2160379017?lang=en_US&edition=fundamental","pubTime":"2021-08-18 23:32","market":"us","language":"en","title":"Analysts upbeat on Tilray's U.S. prospects after MedMen deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2160379017","media":"Dow Jones","summary":"Tilray stock rallies after Alliance Global's Grey said the deal, at a 'reasonable price,' positions ","content":"<p>Tilray stock rallies after Alliance Global's Grey said the deal, at a 'reasonable price,' positions company for stronger growth</p>\n<p>Shares of <a href=\"https://laohu8.com/S/TLRY\">Tilray Inc.</a> rallied Wednesday, on the heels of mostly positive analyst comments on the Canadian cannabis company's announcement to buy a 21% stake in MedMen Enterprises Inc. through the purchase of notes and warrants, to increase its U.S. presence.</p>\n<p>Gotham Green Partners, a backer of MedMen, is the seller on the deal.</p>\n<p>Tilray's stock (TLRY) shot up 4.7% in morning trading, paring earlier intraday gains of as much as 7.2%. Shares of MedMen (MMNFF), which trade over the counter, climbed 25.2%.</p>\n<p>Analyst Aaron Grey of Alliance Global Partners said the transaction could open up an opportunity for Tilray to purchase the remaining portions of MedMen and position it for stronger growth if federal legalization of adult use cannabis takes place. MedMen's current footprint includes dispensaries in New York and California.</p>\n<p>\"While an equity interest in a larger multi-state operator <a href=\"https://laohu8.com/S/MSO\">$(MSO)$</a> would have provided TLRY with greater exposure to current U.S. cannabis markets, given the debt overhang on MMEN, TLRY was able to create its position at a more reasonable price,\" Grey wrote in a research note.</p>\n<p>He maintained his neutral rating on Tilray.</p>\n<p>Meanwhile, Oppenheimer &amp; Co.'s Rupesh Parikh reiterated a perform rating on Tilray and said the company recently disclosed a fiscal 2024 revenue target of $4 billion, including a \"meaningful\" contribution from the U.S. market.</p>\n<p>\"We continue to look favorably upon management's efforts to build out a global cannabis platform, but nearer-term we remain sidelined driven by a continued challenging industry backdrop,\" Parikh said.\"</p>\n<p>Tilray's stock has lost 11.8% over the past three months but has run up 66.3% year to date. In comparison, the <a href=\"https://laohu8.com/S/THCX\">Cannabis ETF</a> (THCX) has gained 14.0% this year while the S&amp;P 500 index has advanced 18.3%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Analysts upbeat on Tilray's U.S. prospects after MedMen deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnalysts upbeat on Tilray's U.S. prospects after MedMen deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-08-18 23:32</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tilray stock rallies after Alliance Global's Grey said the deal, at a 'reasonable price,' positions company for stronger growth</p>\n<p>Shares of <a href=\"https://laohu8.com/S/TLRY\">Tilray Inc.</a> rallied Wednesday, on the heels of mostly positive analyst comments on the Canadian cannabis company's announcement to buy a 21% stake in MedMen Enterprises Inc. through the purchase of notes and warrants, to increase its U.S. presence.</p>\n<p>Gotham Green Partners, a backer of MedMen, is the seller on the deal.</p>\n<p>Tilray's stock (TLRY) shot up 4.7% in morning trading, paring earlier intraday gains of as much as 7.2%. Shares of MedMen (MMNFF), which trade over the counter, climbed 25.2%.</p>\n<p>Analyst Aaron Grey of Alliance Global Partners said the transaction could open up an opportunity for Tilray to purchase the remaining portions of MedMen and position it for stronger growth if federal legalization of adult use cannabis takes place. MedMen's current footprint includes dispensaries in New York and California.</p>\n<p>\"While an equity interest in a larger multi-state operator <a href=\"https://laohu8.com/S/MSO\">$(MSO)$</a> would have provided TLRY with greater exposure to current U.S. cannabis markets, given the debt overhang on MMEN, TLRY was able to create its position at a more reasonable price,\" Grey wrote in a research note.</p>\n<p>He maintained his neutral rating on Tilray.</p>\n<p>Meanwhile, Oppenheimer &amp; Co.'s Rupesh Parikh reiterated a perform rating on Tilray and said the company recently disclosed a fiscal 2024 revenue target of $4 billion, including a \"meaningful\" contribution from the U.S. market.</p>\n<p>\"We continue to look favorably upon management's efforts to build out a global cannabis platform, but nearer-term we remain sidelined driven by a continued challenging industry backdrop,\" Parikh said.\"</p>\n<p>Tilray's stock has lost 11.8% over the past three months but has run up 66.3% year to date. In comparison, the <a href=\"https://laohu8.com/S/THCX\">Cannabis ETF</a> (THCX) has gained 14.0% this year while the S&amp;P 500 index has advanced 18.3%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2160379017","content_text":"Tilray stock rallies after Alliance Global's Grey said the deal, at a 'reasonable price,' positions company for stronger growth\nShares of Tilray Inc. rallied Wednesday, on the heels of mostly positive analyst comments on the Canadian cannabis company's announcement to buy a 21% stake in MedMen Enterprises Inc. through the purchase of notes and warrants, to increase its U.S. presence.\nGotham Green Partners, a backer of MedMen, is the seller on the deal.\nTilray's stock (TLRY) shot up 4.7% in morning trading, paring earlier intraday gains of as much as 7.2%. Shares of MedMen (MMNFF), which trade over the counter, climbed 25.2%.\nAnalyst Aaron Grey of Alliance Global Partners said the transaction could open up an opportunity for Tilray to purchase the remaining portions of MedMen and position it for stronger growth if federal legalization of adult use cannabis takes place. MedMen's current footprint includes dispensaries in New York and California.\n\"While an equity interest in a larger multi-state operator $(MSO)$ would have provided TLRY with greater exposure to current U.S. cannabis markets, given the debt overhang on MMEN, TLRY was able to create its position at a more reasonable price,\" Grey wrote in a research note.\nHe maintained his neutral rating on Tilray.\nMeanwhile, Oppenheimer & Co.'s Rupesh Parikh reiterated a perform rating on Tilray and said the company recently disclosed a fiscal 2024 revenue target of $4 billion, including a \"meaningful\" contribution from the U.S. market.\n\"We continue to look favorably upon management's efforts to build out a global cannabis platform, but nearer-term we remain sidelined driven by a continued challenging industry backdrop,\" Parikh said.\"\nTilray's stock has lost 11.8% over the past three months but has run up 66.3% year to date. In comparison, the Cannabis ETF (THCX) has gained 14.0% this year while the S&P 500 index has advanced 18.3%.","news_type":1,"symbols_score_info":{"TLRY":0.9}},"isVote":1,"tweetType":1,"viewCount":2114,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":839666050,"gmtCreate":1629157226470,"gmtModify":1676529946229,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582022156707091","idStr":"3582022156707091"},"themes":[],"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/839666050","repostId":"2160538227","repostType":4,"isVote":1,"tweetType":1,"viewCount":1525,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":803100979,"gmtCreate":1627426376491,"gmtModify":1703489536591,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582022156707091","idStr":"3582022156707091"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/803100979","repostId":"1170349743","repostType":4,"isVote":1,"tweetType":1,"viewCount":1967,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":176849810,"gmtCreate":1626877335530,"gmtModify":1703479814474,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582022156707091","idStr":"3582022156707091"},"themes":[],"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/176849810","repostId":"2153610465","repostType":4,"isVote":1,"tweetType":1,"viewCount":1690,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":173349271,"gmtCreate":1626621770793,"gmtModify":1703762413265,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582022156707091","idStr":"3582022156707091"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/173349271","repostId":"2152899486","repostType":4,"isVote":1,"tweetType":1,"viewCount":2154,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":143526998,"gmtCreate":1625803424514,"gmtModify":1703748890188,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582022156707091","idStr":"3582022156707091"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/143526998","repostId":"1195657546","repostType":4,"isVote":1,"tweetType":1,"viewCount":1980,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":154334836,"gmtCreate":1625478175925,"gmtModify":1703742420400,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582022156707091","idStr":"3582022156707091"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/154334836","repostId":"1111176344","repostType":4,"repost":{"id":"1111176344","kind":"news","pubTimestamp":1625463785,"share":"https://ttm.financial/m/news/1111176344?lang=en_US&edition=fundamental","pubTime":"2021-07-05 13:43","market":"us","language":"en","title":"Neurodegenerative Disease, Cancer Stocks Among Top Biotech Gainers In 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=1111176344","media":"Benzinga","summary":"Biotech stocks underperformed the broader market in the first half of 2021, with the iShares Nasdaq ","content":"<div>\n<p>Biotech stocks underperformed the broader market in the first half of 2021, with the iShares Nasdaq Biotechnology ETF advancing about 8% year-to-date compared to the roughly 14% gain for the S&P 500 ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/07/21773695/neurodegenerative-disease-cancer-stocks-among-top-biotech-gainers-in-2021\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neurodegenerative Disease, Cancer Stocks Among Top Biotech Gainers In 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurodegenerative Disease, Cancer Stocks Among Top Biotech Gainers In 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-05 13:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/07/21773695/neurodegenerative-disease-cancer-stocks-among-top-biotech-gainers-in-2021><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biotech stocks underperformed the broader market in the first half of 2021, with the iShares Nasdaq Biotechnology ETF advancing about 8% year-to-date compared to the roughly 14% gain for the S&P 500 ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/07/21773695/neurodegenerative-disease-cancer-stocks-among-top-biotech-gainers-in-2021\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PDSB":"PDS Biotechnology Corporation","ENTX":"Entera Bio Ltd.","SAVA":"Cassava Sciences Inc","ATOS":"Atossa Genetics Inc","AVXL":"Anavex Life Sciences Corp.","BTX":"BlackRock Technology and Private Equity Term Trust","MRK":"默沙东","ANVS":"Annovis Bio, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/07/21773695/neurodegenerative-disease-cancer-stocks-among-top-biotech-gainers-in-2021","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111176344","content_text":"Biotech stocks underperformed the broader market in the first half of 2021, with the iShares Nasdaq Biotechnology ETF advancing about 8% year-to-date compared to the roughly 14% gain for the S&P 500 Index.\nIn comparison, the IBB was up 13.6% in the first half of 2020. The strength in the space in the last year was primarily due to risk aversion as the pandemic drove investors into defensive plays such as biotechs. Additionally, companies that kickstarted COVID-19 vaccine programs ran up sharply in 2020.\nThe relatively muted performance so far this year may have to do with the return of risk appetite leading to rotation out of the sector. The rally in vaccine stocks also moderated following emergency use authorizations being accorded for three COVID-19 shots.\nHere are a few stocks that stood out with solid gains amid the muted overall sector performance:\nCassava Sciences Inc : Shares of Cassava, a neurodegenerative disease company, spiked in early February on the back of positive results from the interim analysis of data from an open-label study of simufilam, its lead drug candidate for the treatment of Alzheimer's disease.\nIt hit an intraday high of $117.54 on Feb. 4. After pulling back and consolidating, the stock picked up pace in June. By virtue of the strong advance in the year-to-date period, the stock has tacked on about 1,150%.\nAnnovis Bio Inc : This biopharma that focuses on therapies for neurodegenerative diseases has seen its shares surge by over 1, 060% so far this year.\nThe company's lead drug ANVS401 is being evaluated for multiple indications, including Alzheimer's disease and Parkinson's disease. It works by improving axonal transport by inhibiting the neurotoxic proteins that kill nerve cells. A positive Phase 2 readout for the asset in Alzheimer's disease sent the stock soaring in late April.\nAtossa Therapeutics Inc : The Seattle-based biopharma focusing on treatments for breast cancer and COVID-19 has surged up about 770% year-to-date.\nFrom under $1 at the start of year, the stock rallied to a high of $4.90 in early February on the back of positive Phase 2 data for Endoxifen administered between diagnosis and surgery in breast cancer patients. The upward momentum faltered subsequently and the stock pulled back to a low of $1.48 on April 19.\nAtossa recovered from there and the rally picked up steam in June amid the release of positive final Phase 2 data for Endoxifen and inclusion in the Russell 2000 and 3000 indexes.\nEntera Bio Ltd. : The biopharma, which develops orally delivered large molecule therapeutics for use in areas with significant unmet medical need, has seen its shares surge higher by over 460% so far this year.\nThe company's pipeline consists of EB613, which is being evaluated for osteoporosis, and EB612 for hypoparathyroidism.\nEntera Bio shares jumped in early April when it reported positive topline biomarker data for EB613. The stock received a shot in the arm from the positive six-month bone mineral density results from the Phase 2 clinical trial of EB613, which the company reportedlast week.\nPDS Biotechnology Corp : PDS has gained about 450% year-to-date. The company has oncology and infectious disease programs.\nThe gains for the year-to-date period reflected the presentation of data from the Phase 2 combination study with PDS0101 in HPV-associated tumors at the ASCO conference, and also its COVID-19 program.\nAnavex Life Sciences Corp. shares have gained about 430% year-to-date. The company is developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders.\nThe company's lead product candidate blarcamesine (ANAVEX2-73) is being evaluated for multiple indications. The predictive biomarker of response established with SIGMAR1 mRNA expression correlates significantly with responses in primary and secondary clinical efficacy endpoints from the proof-of-concept Phase 2 trial in Parkinson's disease, the company announced.\nBrooklyn ImmunoTherapeutics Inc : This New York-based gene and cell therapy company has clocked gains of about 375% year-to-date.\nThe company is focused on exploring the role cytokine-based therapy can have in treating patients with cancer. The company is also exploring opportunities to advance oncology, blood disorder and monogenic disease therapies using highly innovative gene editing/cell therapy technology.\nBrooklyn initiated a mid-stage study of IRX-2 in combination with Merck & Co., Inc.'s Keytruda and chemotherapy in triple-negative breast cancer.\nIn March, the company completed its reverse merger with NTN Buzztime.\nHoward Federoff took over as CEO in early April. Later that month, the company acquired an exclusive license for mRNA gene editing and cell therapies technology of Factor Bioscience and Novellus Therapeutics, pursuant to an exercise of a previously announced option.\nThe company has also been added to the Russell 3000 Index.\nBrooklyn's most advanced program is the study of the lead asset IRX-2, a human cell-derived biologic with multiple active cytokine components in patients with head and neck cancer. With commercialization years away — and ultimately contingent on IRX-2 clearing clinical and regulatory hurdles — the valuation of Brooklyn looks a little stretched.","news_type":1,"symbols_score_info":{"MRK":0.9,"SAVA":0.9,"BTX":0.9,"AVXL":0.9,"PDSB":0.9,"ATOS":0.9,"ANVS":0.9,"ENTX":0.9}},"isVote":1,"tweetType":1,"viewCount":2032,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":154335628,"gmtCreate":1625478130964,"gmtModify":1703742419254,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582022156707091","idStr":"3582022156707091"},"themes":[],"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/154335628","repostId":"1109703914","repostType":4,"repost":{"id":"1109703914","kind":"news","pubTimestamp":1625464355,"share":"https://ttm.financial/m/news/1109703914?lang=en_US&edition=fundamental","pubTime":"2021-07-05 13:52","market":"us","language":"en","title":"Is the Stock Market Open or Closed on Independence Day?","url":"https://stock-news.laohu8.com/highlight/detail?id=1109703914","media":"Thestreet","summary":"Independence Day in the U.S. is for many a picnic-and-beach day. But July 4 this year falls on a Sunday, which in the United States isn't a trading day.So will the major markets open or close for the holiday?The New York Stock Exchange and the Nasdaq will, in fact, be closed on Monday, July 5, to celebrate Independence Day.It's one of nine full-closing daysfor the stock market this year.For instance, the stock market will close for Thanksgiving on Thursday, Nov. 25. On Friday, Nov. 26, trading i","content":"<p>Independence Day in the U.S. is for many a picnic-and-beach day. But July 4 this year falls on a Sunday, which in the United States isn't a trading day.</p>\n<p>So will the major markets open or close for the holiday?</p>\n<p>The New York Stock Exchange and the Nasdaq will, in fact, be closed on Monday, July 5, to celebrate Independence Day.</p>\n<p>It's&nbsp;one of nine full-closing daysfor the stock market this year.</p>\n<p>For instance, the stock market will close for Thanksgiving on Thursday, Nov. 25. On Friday, Nov. 26, trading is scheduled for a bit more than a half-day, 9:30 a.m. to 1 p.m. ET.</p>\n<p>Normal stock-trading hours run 9:30 a.m. to 4 p.m. ET.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is the Stock Market Open or Closed on Independence Day?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs the Stock Market Open or Closed on Independence Day?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-05 13:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/independence-day-stock-markets-trading-hours><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Independence Day in the U.S. is for many a picnic-and-beach day. But July 4 this year falls on a Sunday, which in the United States isn't a trading day.\nSo will the major markets open or close for the...</p>\n\n<a href=\"https://www.thestreet.com/investing/independence-day-stock-markets-trading-hours\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"source_url":"https://www.thestreet.com/investing/independence-day-stock-markets-trading-hours","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109703914","content_text":"Independence Day in the U.S. is for many a picnic-and-beach day. But July 4 this year falls on a Sunday, which in the United States isn't a trading day.\nSo will the major markets open or close for the holiday?\nThe New York Stock Exchange and the Nasdaq will, in fact, be closed on Monday, July 5, to celebrate Independence Day.\nIt's one of nine full-closing daysfor the stock market this year.\nFor instance, the stock market will close for Thanksgiving on Thursday, Nov. 25. On Friday, Nov. 26, trading is scheduled for a bit more than a half-day, 9:30 a.m. to 1 p.m. ET.\nNormal stock-trading hours run 9:30 a.m. to 4 p.m. ET.","news_type":1,"symbols_score_info":{".SPX":0.9,".IXIC":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":2038,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":155980351,"gmtCreate":1625369086473,"gmtModify":1703740878799,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582022156707091","idStr":"3582022156707091"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/155980351","repostId":"1146176335","repostType":4,"repost":{"id":"1146176335","kind":"news","pubTimestamp":1625277627,"share":"https://ttm.financial/m/news/1146176335?lang=en_US&edition=fundamental","pubTime":"2021-07-03 10:00","market":"us","language":"en","title":"Can Alibaba Turn Around Its Woes in the Second Half of 2021?","url":"https://stock-news.laohu8.com/highlight/detail?id=1146176335","media":"The Street","summary":"Alibaba has been a sore laggard compared with its large- and mega-cap peers. Can that change in the second half of 2021?Alibaba  -Get Report has been a total dog so far this year. Shares were trading well into the fourth quarter of 2020 but then a string of issues pummeled the stock.Regulators disrupted Ant's initial public offering, then dug deeper on Alibaba and dialed up the heat.Investors don’t like regulatory issues as it is but particularly when we’re dealing with Chinese regulators.Howeve","content":"<blockquote>\n Alibaba has been a sore laggard compared with its large- and mega-cap peers. Can that change in the second half of 2021?\n</blockquote>\n<p>Alibaba&nbsp;(<b>BABA</b>) -Get Report&nbsp;has been a total dog so far this year. Shares were trading well into the fourth quarter of 2020 but then a string of issues pummeled the stock.</p>\n<p>Regulators disrupted Ant's initial public offering, then dug deeper on Alibaba and dialed up the heat.</p>\n<p>Investors don’t like regulatory issues as it is but particularly when we’re dealing with Chinese regulators.</p>\n<p>However, in April, Alibaba paid a smaller-than-expectedbut still record fine, hoping to puts its regulatory issues behind it. Still, the stock hasn’t responded the way bulls were hoping.</p>\n<p>All of this comes as the S&amp;P 500 and Nasdaq continue to grind outnew all-time highs.</p>\n<p>It also comes as FAANG stocks continue to trade incredibly well. Alphabet&nbsp;(<b>GOOGL</b>) -Get Reportis the top performerwith a near-40% gain in the first half of the year, while Netflix&nbsp;(<b>NFLX</b>) -Get Report&nbsp;is the worst, with a 2.3% drop.</p>\n<p>Alibaba has a similar first-half performance, down 2.6%. However, it’s doing far worse from the highs, down more than 30%.</p>\n<p>Can it turn around its woes in the second half and start rallying higher?</p>\n<p><img src=\"https://static.tigerbbs.com/9975f383919ff8cfc34fca49a32d8e8f\" tg-width=\"700\" tg-height=\"494\"></p>\n<p>Call me a hopeless optimist, but I feel that Alibaba can have a solid second-half performance.</p>\n<p>The overall market has done too well and so has large-cap tech. The fundamentals of the business are intact and growth is strong. It’s like Amazon&nbsp;(<b>AMZN</b>) -Get Report.Eventually, it will perform better&nbsp;- it’s a question of “when” and not “if.”</p>\n<p>Shares continue to hold the $210 to $212 area and have recently cleared downtrend resistance (blue line). That said, there’s plenty of overhead hurdles.</p>\n<p>Specifically, Alibaba stock is struggling with the 21-week moving average, as well as the 21-month and 10-month moving averages.</p>\n<p>Let’s be clear: There are not a lot of bullish technical components here. If Alibaba stock could hold the 10-week moving average on this week’s dip, I’d feel better about it.</p>\n<p>However, as long as it can hold up over the $210 level and really, the 200-week moving average, I feel okay about Alibaba going into the next six months.</p>\n<p>A push over $235 - thus putting it over all of the moving average hurdles mentioned above - could open up a run to $250, then $263. Above $275 and $300 is in play.</p>\n<p>Keep the risk in mind but this could be a solid second-half rebound play.</p>","source":"lsy1610613172068","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Can Alibaba Turn Around Its Woes in the Second Half of 2021?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCan Alibaba Turn Around Its Woes in the Second Half of 2021?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-03 10:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/alibaba-baba-stock-second-half-2021-trading?puc=yahoo&cm_ven=YAHOO><strong>The Street</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alibaba has been a sore laggard compared with its large- and mega-cap peers. Can that change in the second half of 2021?\n\nAlibaba (BABA) -Get Report has been a total dog so far this year. Shares were ...</p>\n\n<a href=\"https://www.thestreet.com/investing/alibaba-baba-stock-second-half-2021-trading?puc=yahoo&cm_ven=YAHOO\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BABA":"阿里巴巴","09618":"京东集团-SW"},"source_url":"https://www.thestreet.com/investing/alibaba-baba-stock-second-half-2021-trading?puc=yahoo&cm_ven=YAHOO","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146176335","content_text":"Alibaba has been a sore laggard compared with its large- and mega-cap peers. Can that change in the second half of 2021?\n\nAlibaba (BABA) -Get Report has been a total dog so far this year. Shares were trading well into the fourth quarter of 2020 but then a string of issues pummeled the stock.\nRegulators disrupted Ant's initial public offering, then dug deeper on Alibaba and dialed up the heat.\nInvestors don’t like regulatory issues as it is but particularly when we’re dealing with Chinese regulators.\nHowever, in April, Alibaba paid a smaller-than-expectedbut still record fine, hoping to puts its regulatory issues behind it. Still, the stock hasn’t responded the way bulls were hoping.\nAll of this comes as the S&P 500 and Nasdaq continue to grind outnew all-time highs.\nIt also comes as FAANG stocks continue to trade incredibly well. Alphabet (GOOGL) -Get Reportis the top performerwith a near-40% gain in the first half of the year, while Netflix (NFLX) -Get Report is the worst, with a 2.3% drop.\nAlibaba has a similar first-half performance, down 2.6%. However, it’s doing far worse from the highs, down more than 30%.\nCan it turn around its woes in the second half and start rallying higher?\n\nCall me a hopeless optimist, but I feel that Alibaba can have a solid second-half performance.\nThe overall market has done too well and so has large-cap tech. The fundamentals of the business are intact and growth is strong. It’s like Amazon (AMZN) -Get Report.Eventually, it will perform better - it’s a question of “when” and not “if.”\nShares continue to hold the $210 to $212 area and have recently cleared downtrend resistance (blue line). That said, there’s plenty of overhead hurdles.\nSpecifically, Alibaba stock is struggling with the 21-week moving average, as well as the 21-month and 10-month moving averages.\nLet’s be clear: There are not a lot of bullish technical components here. If Alibaba stock could hold the 10-week moving average on this week’s dip, I’d feel better about it.\nHowever, as long as it can hold up over the $210 level and really, the 200-week moving average, I feel okay about Alibaba going into the next six months.\nA push over $235 - thus putting it over all of the moving average hurdles mentioned above - could open up a run to $250, then $263. Above $275 and $300 is in play.\nKeep the risk in mind but this could be a solid second-half rebound play.","news_type":1,"symbols_score_info":{"09618":0.9,"BABA":0.9}},"isVote":1,"tweetType":1,"viewCount":2821,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":152366771,"gmtCreate":1625271209393,"gmtModify":1703739627310,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582022156707091","idStr":"3582022156707091"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/152366771","repostId":"2148181808","repostType":4,"isVote":1,"tweetType":1,"viewCount":1596,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":152368056,"gmtCreate":1625271119175,"gmtModify":1703739623563,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582022156707091","idStr":"3582022156707091"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/152368056","repostId":"2148870441","repostType":4,"isVote":1,"tweetType":1,"viewCount":405,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123506627,"gmtCreate":1624427703869,"gmtModify":1703836375456,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582022156707091","idStr":"3582022156707091"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/123506627","repostId":"2145066250","repostType":4,"isVote":1,"tweetType":1,"viewCount":618,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123501714,"gmtCreate":1624427620738,"gmtModify":1703836372839,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582022156707091","idStr":"3582022156707091"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/123501714","repostId":"1174011543","repostType":4,"repost":{"id":"1174011543","kind":"news","pubTimestamp":1624425845,"share":"https://ttm.financial/m/news/1174011543?lang=en_US&edition=fundamental","pubTime":"2021-06-23 13:24","market":"us","language":"en","title":"FDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=1174011543","media":"WSJ","summary":"The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the obje","content":"<p>The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the objection of agency statisticians who said there was insufficient evidence to support approval, according to newly released internal memos.</p>\n<p>In the internal memos released Tuesday, FDA officials discussed whether to approve the drug fromBiogenInc.BIIB-1.71%over objections from the agency’s drug statistics office, which said that clinical trial data fell short of the proof typically required to put a new product on the market.</p>\n<p>Ultimately, top officials decided that the evidence indicating that the drug worked, while inconclusive, was strong enough to allow doctors and patients to decide for themselves whether to take it, according to the memos.</p>\n<p>“FDA, then, is faced with a situation where the available evidence on the clinical endpoints is short of what we would require for standard approval of aducanumab,” wrote Peter Stein, director of the FDA’s office of new drugs, in a memo detailing his support for approval. “At the same time, patients with [Alzheimer’s] have a serious, progressive, ultimately fatal disease and are desperate for treatments.”</p>\n<p>The FDA made public its internal deliberations as it faces criticism from some doctors and scientists over the June 7 approval of the drug, called Aduhelm.</p>\n<p>The critics say the FDA ignored the scientific standards it typically holds drugmakers to and could prompt the federal government to spend billions of dollars on a drug that may not work.</p>\n<p>“While I fully support the Center’s recent decision to approve the therapy, I acknowledge that there are different opinions about this decision, including within FDA, and there likely will continue to be questions around our process for review and the data we considered to support the approval,” said FDA Acting Commissioner Janet Woodcock. “In the end, an experienced group of medical reviewers at FDA concluded that there was sufficient evidence to approve the Alzheimer’s therapy via the accelerated approval pathway.”</p>\n<p>Supporters say the FDA decision provides a lifeline to patients who have lacked any medicine promising to slow the progression of Alzheimer’s, and that the decision couldspur the development of more, better medicines.</p>\n<p>The agency usually releases approval documents after a decision, though not typically as quickly as it did this time. The 83 pages of memos appear to be a portion of the FDA’s deliberations, largely reflecting the exchanges of top officials.</p>\n<p>Tristan Massie, a biostatistics reviewer for the FDA, “does not agree that the totality of the data provides sufficient evidence to support the efficacy of aducanumab in Alzheimer’s disease and does not recommend approval,” one of the internal documents shows.</p>\n<p>Patrizia Cavazzoni, the FDA’s top-ranking drug-evaluation official, wrote in another memo that the agency’s drug biostatistics office “provided documentation for its recommendation that substantial evidence of effectiveness had not been provided in the application.”</p>\n<p>That office’s full dissenting analysis wasn’t included in the materials made available Tuesday, but portions of it were.</p>\n<p>Despite the objections, Dr. Cavazzoni wrote that Biogen had met the requirements for an “accelerated approval,” a type of regulatory clearance that allows a drug to be marketed even when there remains uncertainty about its clinical benefit if it fills an unmet need for a serious disease and has effects against a biological sign of the disease.</p>\n<p>Dr. Cavazzoni wrote that Aduhelm met that standard because of its effect of reducing a sticky substance called amyloid which “is reasonably likely to predict clinical benefit.”</p>\n<p>Some doctors and scientists saytargeting the amyloid plaqueshasn’t been proven to slow Alzheimer’s. Some members of a panel of advisers that recommended the FDA reject the drug haveresigned from the committee, citing the agency’s approval.</p>\n<p>Biogen listed the price of Aduhelm at $56,000 a year, and patients and Medicare could also face testing charges.</p>\n<p>About six million Americans suffer from Alzheimer’s, a progressive condition that robs people of their memories and cognitive abilities. Biogen has said that as many as two million of them may benefit from the medicine.</p>\n<p>The FDA approval sent Biogen’s stock soaring. The company has said it expects only minimal revenue from the drug this year, in part because of the logistical challenges in administering the medicine, but that sales would begin to increase next year.</p>\n<p>Analysts estimate sales of $946.3 million in 2022, according to FactSet. Sales are seen growing to $5.2 billion in 2026.</p>\n<p>The memos show FDA officials attempting to balance the subpar study data for Aduhelm with the desire of Alzheimer’s patients and their families to try any new treatment that might help.</p>\n<p>“There remains residual uncertainty regarding clinical benefit,” Dr. Stein wrote. But if the FDA were to wait for the company to finish another clinical study, “any approval would occur after a multiple year delay” and patients “could suffer irreversible loss of brain neurons and cognitive function and memory,” he wrote.</p>\n<p>The FDA said it plans to release more documents regarding its decision making as early as next week.</p>\n<p>The FDA’s approval was based primarily on two large Phase 3 clinical trials launched by Biogen to prove its drug helped slow the cognitive decline of people with early-stage Alzheimer’s.</p>\n<p>In March 2019, the companyhalted the studies earlyafter an independent monitoring board concluded the drug was unlikely to help patients.</p>\n<p>Seven months later, however,the company made a surprising reversaland said it was now planning to seek FDA approval after conducting additional analyses of trial data that came in after the studies were halted. The company said its analyses found the drug was successful in one study but failed in the second.</p>\n<p>The FDA memos provide some new details on Biogen’s about-face. In June 2019, the company met with FDA officials and both sides agreed the studies shouldn’t have been stopped, according to a “summary memorandum” document.</p>\n<p>At the meeting, FDA officials recommended that Biogen analyze the studies further to understand if it was still possible to draw conclusions from the data, despite the halt of the trials and conflicting results.</p>\n<p>Several months later, in October 2019, the agency and company met again and agreed that the studies could still be used to evaluate the drug’s effectiveness, according to the memo.</p>\n<p>The following day, on Oct. 22, Biogen announcedit would seek approval for the medicine, sending up its share price and adding billions of dollars to its market value.</p>\n<p>The company had been quietly re-examining the data for months, but didn’t have the confidence to move forward until the latest meeting with FDA officials, Biogen Chief Executive Michel Vounatsos said in an interview at the time.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-23 13:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/fda-approved-biogen-alzheimers-drug-despite-some-staff-concerns-11624393800?mod=hp_lead_pos2><strong>WSJ</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the objection of agency statisticians who said there was insufficient evidence to support approval, ...</p>\n\n<a href=\"https://www.wsj.com/articles/fda-approved-biogen-alzheimers-drug-despite-some-staff-concerns-11624393800?mod=hp_lead_pos2\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.wsj.com/articles/fda-approved-biogen-alzheimers-drug-despite-some-staff-concerns-11624393800?mod=hp_lead_pos2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174011543","content_text":"The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the objection of agency statisticians who said there was insufficient evidence to support approval, according to newly released internal memos.\nIn the internal memos released Tuesday, FDA officials discussed whether to approve the drug fromBiogenInc.BIIB-1.71%over objections from the agency’s drug statistics office, which said that clinical trial data fell short of the proof typically required to put a new product on the market.\nUltimately, top officials decided that the evidence indicating that the drug worked, while inconclusive, was strong enough to allow doctors and patients to decide for themselves whether to take it, according to the memos.\n“FDA, then, is faced with a situation where the available evidence on the clinical endpoints is short of what we would require for standard approval of aducanumab,” wrote Peter Stein, director of the FDA’s office of new drugs, in a memo detailing his support for approval. “At the same time, patients with [Alzheimer’s] have a serious, progressive, ultimately fatal disease and are desperate for treatments.”\nThe FDA made public its internal deliberations as it faces criticism from some doctors and scientists over the June 7 approval of the drug, called Aduhelm.\nThe critics say the FDA ignored the scientific standards it typically holds drugmakers to and could prompt the federal government to spend billions of dollars on a drug that may not work.\n“While I fully support the Center’s recent decision to approve the therapy, I acknowledge that there are different opinions about this decision, including within FDA, and there likely will continue to be questions around our process for review and the data we considered to support the approval,” said FDA Acting Commissioner Janet Woodcock. “In the end, an experienced group of medical reviewers at FDA concluded that there was sufficient evidence to approve the Alzheimer’s therapy via the accelerated approval pathway.”\nSupporters say the FDA decision provides a lifeline to patients who have lacked any medicine promising to slow the progression of Alzheimer’s, and that the decision couldspur the development of more, better medicines.\nThe agency usually releases approval documents after a decision, though not typically as quickly as it did this time. The 83 pages of memos appear to be a portion of the FDA’s deliberations, largely reflecting the exchanges of top officials.\nTristan Massie, a biostatistics reviewer for the FDA, “does not agree that the totality of the data provides sufficient evidence to support the efficacy of aducanumab in Alzheimer’s disease and does not recommend approval,” one of the internal documents shows.\nPatrizia Cavazzoni, the FDA’s top-ranking drug-evaluation official, wrote in another memo that the agency’s drug biostatistics office “provided documentation for its recommendation that substantial evidence of effectiveness had not been provided in the application.”\nThat office’s full dissenting analysis wasn’t included in the materials made available Tuesday, but portions of it were.\nDespite the objections, Dr. Cavazzoni wrote that Biogen had met the requirements for an “accelerated approval,” a type of regulatory clearance that allows a drug to be marketed even when there remains uncertainty about its clinical benefit if it fills an unmet need for a serious disease and has effects against a biological sign of the disease.\nDr. Cavazzoni wrote that Aduhelm met that standard because of its effect of reducing a sticky substance called amyloid which “is reasonably likely to predict clinical benefit.”\nSome doctors and scientists saytargeting the amyloid plaqueshasn’t been proven to slow Alzheimer’s. Some members of a panel of advisers that recommended the FDA reject the drug haveresigned from the committee, citing the agency’s approval.\nBiogen listed the price of Aduhelm at $56,000 a year, and patients and Medicare could also face testing charges.\nAbout six million Americans suffer from Alzheimer’s, a progressive condition that robs people of their memories and cognitive abilities. Biogen has said that as many as two million of them may benefit from the medicine.\nThe FDA approval sent Biogen’s stock soaring. The company has said it expects only minimal revenue from the drug this year, in part because of the logistical challenges in administering the medicine, but that sales would begin to increase next year.\nAnalysts estimate sales of $946.3 million in 2022, according to FactSet. Sales are seen growing to $5.2 billion in 2026.\nThe memos show FDA officials attempting to balance the subpar study data for Aduhelm with the desire of Alzheimer’s patients and their families to try any new treatment that might help.\n“There remains residual uncertainty regarding clinical benefit,” Dr. Stein wrote. But if the FDA were to wait for the company to finish another clinical study, “any approval would occur after a multiple year delay” and patients “could suffer irreversible loss of brain neurons and cognitive function and memory,” he wrote.\nThe FDA said it plans to release more documents regarding its decision making as early as next week.\nThe FDA’s approval was based primarily on two large Phase 3 clinical trials launched by Biogen to prove its drug helped slow the cognitive decline of people with early-stage Alzheimer’s.\nIn March 2019, the companyhalted the studies earlyafter an independent monitoring board concluded the drug was unlikely to help patients.\nSeven months later, however,the company made a surprising reversaland said it was now planning to seek FDA approval after conducting additional analyses of trial data that came in after the studies were halted. The company said its analyses found the drug was successful in one study but failed in the second.\nThe FDA memos provide some new details on Biogen’s about-face. In June 2019, the company met with FDA officials and both sides agreed the studies shouldn’t have been stopped, according to a “summary memorandum” document.\nAt the meeting, FDA officials recommended that Biogen analyze the studies further to understand if it was still possible to draw conclusions from the data, despite the halt of the trials and conflicting results.\nSeveral months later, in October 2019, the agency and company met again and agreed that the studies could still be used to evaluate the drug’s effectiveness, according to the memo.\nThe following day, on Oct. 22, Biogen announcedit would seek approval for the medicine, sending up its share price and adding billions of dollars to its market value.\nThe company had been quietly re-examining the data for months, but didn’t have the confidence to move forward until the latest meeting with FDA officials, Biogen Chief Executive Michel Vounatsos said in an interview at the time.","news_type":1,"symbols_score_info":{"BIIB":0.9}},"isVote":1,"tweetType":1,"viewCount":300,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":154335628,"gmtCreate":1625478130964,"gmtModify":1703742419254,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/154335628","repostId":"1109703914","repostType":4,"repost":{"id":"1109703914","kind":"news","pubTimestamp":1625464355,"share":"https://ttm.financial/m/news/1109703914?lang=en_US&edition=fundamental","pubTime":"2021-07-05 13:52","market":"us","language":"en","title":"Is the Stock Market Open or Closed on Independence Day?","url":"https://stock-news.laohu8.com/highlight/detail?id=1109703914","media":"Thestreet","summary":"Independence Day in the U.S. is for many a picnic-and-beach day. But July 4 this year falls on a Sunday, which in the United States isn't a trading day.So will the major markets open or close for the holiday?The New York Stock Exchange and the Nasdaq will, in fact, be closed on Monday, July 5, to celebrate Independence Day.It's one of nine full-closing daysfor the stock market this year.For instance, the stock market will close for Thanksgiving on Thursday, Nov. 25. On Friday, Nov. 26, trading i","content":"<p>Independence Day in the U.S. is for many a picnic-and-beach day. But July 4 this year falls on a Sunday, which in the United States isn't a trading day.</p>\n<p>So will the major markets open or close for the holiday?</p>\n<p>The New York Stock Exchange and the Nasdaq will, in fact, be closed on Monday, July 5, to celebrate Independence Day.</p>\n<p>It's&nbsp;one of nine full-closing daysfor the stock market this year.</p>\n<p>For instance, the stock market will close for Thanksgiving on Thursday, Nov. 25. On Friday, Nov. 26, trading is scheduled for a bit more than a half-day, 9:30 a.m. to 1 p.m. ET.</p>\n<p>Normal stock-trading hours run 9:30 a.m. to 4 p.m. ET.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is the Stock Market Open or Closed on Independence Day?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs the Stock Market Open or Closed on Independence Day?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-05 13:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/independence-day-stock-markets-trading-hours><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Independence Day in the U.S. is for many a picnic-and-beach day. But July 4 this year falls on a Sunday, which in the United States isn't a trading day.\nSo will the major markets open or close for the...</p>\n\n<a href=\"https://www.thestreet.com/investing/independence-day-stock-markets-trading-hours\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"source_url":"https://www.thestreet.com/investing/independence-day-stock-markets-trading-hours","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109703914","content_text":"Independence Day in the U.S. is for many a picnic-and-beach day. But July 4 this year falls on a Sunday, which in the United States isn't a trading day.\nSo will the major markets open or close for the holiday?\nThe New York Stock Exchange and the Nasdaq will, in fact, be closed on Monday, July 5, to celebrate Independence Day.\nIt's one of nine full-closing daysfor the stock market this year.\nFor instance, the stock market will close for Thanksgiving on Thursday, Nov. 25. On Friday, Nov. 26, trading is scheduled for a bit more than a half-day, 9:30 a.m. to 1 p.m. ET.\nNormal stock-trading hours run 9:30 a.m. to 4 p.m. ET.","news_type":1,"symbols_score_info":{".SPX":0.9,".IXIC":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":2038,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":143526998,"gmtCreate":1625803424514,"gmtModify":1703748890188,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/143526998","repostId":"1195657546","repostType":4,"isVote":1,"tweetType":1,"viewCount":1980,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":831205881,"gmtCreate":1629328295443,"gmtModify":1676530001835,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/831205881","repostId":"2160379017","repostType":4,"repost":{"id":"2160379017","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1629300766,"share":"https://ttm.financial/m/news/2160379017?lang=en_US&edition=fundamental","pubTime":"2021-08-18 23:32","market":"us","language":"en","title":"Analysts upbeat on Tilray's U.S. prospects after MedMen deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2160379017","media":"Dow Jones","summary":"Tilray stock rallies after Alliance Global's Grey said the deal, at a 'reasonable price,' positions ","content":"<p>Tilray stock rallies after Alliance Global's Grey said the deal, at a 'reasonable price,' positions company for stronger growth</p>\n<p>Shares of <a href=\"https://laohu8.com/S/TLRY\">Tilray Inc.</a> rallied Wednesday, on the heels of mostly positive analyst comments on the Canadian cannabis company's announcement to buy a 21% stake in MedMen Enterprises Inc. through the purchase of notes and warrants, to increase its U.S. presence.</p>\n<p>Gotham Green Partners, a backer of MedMen, is the seller on the deal.</p>\n<p>Tilray's stock (TLRY) shot up 4.7% in morning trading, paring earlier intraday gains of as much as 7.2%. Shares of MedMen (MMNFF), which trade over the counter, climbed 25.2%.</p>\n<p>Analyst Aaron Grey of Alliance Global Partners said the transaction could open up an opportunity for Tilray to purchase the remaining portions of MedMen and position it for stronger growth if federal legalization of adult use cannabis takes place. MedMen's current footprint includes dispensaries in New York and California.</p>\n<p>\"While an equity interest in a larger multi-state operator <a href=\"https://laohu8.com/S/MSO\">$(MSO)$</a> would have provided TLRY with greater exposure to current U.S. cannabis markets, given the debt overhang on MMEN, TLRY was able to create its position at a more reasonable price,\" Grey wrote in a research note.</p>\n<p>He maintained his neutral rating on Tilray.</p>\n<p>Meanwhile, Oppenheimer &amp; Co.'s Rupesh Parikh reiterated a perform rating on Tilray and said the company recently disclosed a fiscal 2024 revenue target of $4 billion, including a \"meaningful\" contribution from the U.S. market.</p>\n<p>\"We continue to look favorably upon management's efforts to build out a global cannabis platform, but nearer-term we remain sidelined driven by a continued challenging industry backdrop,\" Parikh said.\"</p>\n<p>Tilray's stock has lost 11.8% over the past three months but has run up 66.3% year to date. In comparison, the <a href=\"https://laohu8.com/S/THCX\">Cannabis ETF</a> (THCX) has gained 14.0% this year while the S&amp;P 500 index has advanced 18.3%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Analysts upbeat on Tilray's U.S. prospects after MedMen deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnalysts upbeat on Tilray's U.S. prospects after MedMen deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-08-18 23:32</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tilray stock rallies after Alliance Global's Grey said the deal, at a 'reasonable price,' positions company for stronger growth</p>\n<p>Shares of <a href=\"https://laohu8.com/S/TLRY\">Tilray Inc.</a> rallied Wednesday, on the heels of mostly positive analyst comments on the Canadian cannabis company's announcement to buy a 21% stake in MedMen Enterprises Inc. through the purchase of notes and warrants, to increase its U.S. presence.</p>\n<p>Gotham Green Partners, a backer of MedMen, is the seller on the deal.</p>\n<p>Tilray's stock (TLRY) shot up 4.7% in morning trading, paring earlier intraday gains of as much as 7.2%. Shares of MedMen (MMNFF), which trade over the counter, climbed 25.2%.</p>\n<p>Analyst Aaron Grey of Alliance Global Partners said the transaction could open up an opportunity for Tilray to purchase the remaining portions of MedMen and position it for stronger growth if federal legalization of adult use cannabis takes place. MedMen's current footprint includes dispensaries in New York and California.</p>\n<p>\"While an equity interest in a larger multi-state operator <a href=\"https://laohu8.com/S/MSO\">$(MSO)$</a> would have provided TLRY with greater exposure to current U.S. cannabis markets, given the debt overhang on MMEN, TLRY was able to create its position at a more reasonable price,\" Grey wrote in a research note.</p>\n<p>He maintained his neutral rating on Tilray.</p>\n<p>Meanwhile, Oppenheimer &amp; Co.'s Rupesh Parikh reiterated a perform rating on Tilray and said the company recently disclosed a fiscal 2024 revenue target of $4 billion, including a \"meaningful\" contribution from the U.S. market.</p>\n<p>\"We continue to look favorably upon management's efforts to build out a global cannabis platform, but nearer-term we remain sidelined driven by a continued challenging industry backdrop,\" Parikh said.\"</p>\n<p>Tilray's stock has lost 11.8% over the past three months but has run up 66.3% year to date. In comparison, the <a href=\"https://laohu8.com/S/THCX\">Cannabis ETF</a> (THCX) has gained 14.0% this year while the S&amp;P 500 index has advanced 18.3%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2160379017","content_text":"Tilray stock rallies after Alliance Global's Grey said the deal, at a 'reasonable price,' positions company for stronger growth\nShares of Tilray Inc. rallied Wednesday, on the heels of mostly positive analyst comments on the Canadian cannabis company's announcement to buy a 21% stake in MedMen Enterprises Inc. through the purchase of notes and warrants, to increase its U.S. presence.\nGotham Green Partners, a backer of MedMen, is the seller on the deal.\nTilray's stock (TLRY) shot up 4.7% in morning trading, paring earlier intraday gains of as much as 7.2%. Shares of MedMen (MMNFF), which trade over the counter, climbed 25.2%.\nAnalyst Aaron Grey of Alliance Global Partners said the transaction could open up an opportunity for Tilray to purchase the remaining portions of MedMen and position it for stronger growth if federal legalization of adult use cannabis takes place. MedMen's current footprint includes dispensaries in New York and California.\n\"While an equity interest in a larger multi-state operator $(MSO)$ would have provided TLRY with greater exposure to current U.S. cannabis markets, given the debt overhang on MMEN, TLRY was able to create its position at a more reasonable price,\" Grey wrote in a research note.\nHe maintained his neutral rating on Tilray.\nMeanwhile, Oppenheimer & Co.'s Rupesh Parikh reiterated a perform rating on Tilray and said the company recently disclosed a fiscal 2024 revenue target of $4 billion, including a \"meaningful\" contribution from the U.S. market.\n\"We continue to look favorably upon management's efforts to build out a global cannabis platform, but nearer-term we remain sidelined driven by a continued challenging industry backdrop,\" Parikh said.\"\nTilray's stock has lost 11.8% over the past three months but has run up 66.3% year to date. In comparison, the Cannabis ETF (THCX) has gained 14.0% this year while the S&P 500 index has advanced 18.3%.","news_type":1,"symbols_score_info":{"TLRY":0.9}},"isVote":1,"tweetType":1,"viewCount":2114,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":173349271,"gmtCreate":1626621770793,"gmtModify":1703762413265,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/173349271","repostId":"2152899486","repostType":4,"isVote":1,"tweetType":1,"viewCount":2154,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":155980351,"gmtCreate":1625369086473,"gmtModify":1703740878799,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/155980351","repostId":"1146176335","repostType":4,"repost":{"id":"1146176335","kind":"news","pubTimestamp":1625277627,"share":"https://ttm.financial/m/news/1146176335?lang=en_US&edition=fundamental","pubTime":"2021-07-03 10:00","market":"us","language":"en","title":"Can Alibaba Turn Around Its Woes in the Second Half of 2021?","url":"https://stock-news.laohu8.com/highlight/detail?id=1146176335","media":"The Street","summary":"Alibaba has been a sore laggard compared with its large- and mega-cap peers. Can that change in the second half of 2021?Alibaba  -Get Report has been a total dog so far this year. Shares were trading well into the fourth quarter of 2020 but then a string of issues pummeled the stock.Regulators disrupted Ant's initial public offering, then dug deeper on Alibaba and dialed up the heat.Investors don’t like regulatory issues as it is but particularly when we’re dealing with Chinese regulators.Howeve","content":"<blockquote>\n Alibaba has been a sore laggard compared with its large- and mega-cap peers. Can that change in the second half of 2021?\n</blockquote>\n<p>Alibaba&nbsp;(<b>BABA</b>) -Get Report&nbsp;has been a total dog so far this year. Shares were trading well into the fourth quarter of 2020 but then a string of issues pummeled the stock.</p>\n<p>Regulators disrupted Ant's initial public offering, then dug deeper on Alibaba and dialed up the heat.</p>\n<p>Investors don’t like regulatory issues as it is but particularly when we’re dealing with Chinese regulators.</p>\n<p>However, in April, Alibaba paid a smaller-than-expectedbut still record fine, hoping to puts its regulatory issues behind it. Still, the stock hasn’t responded the way bulls were hoping.</p>\n<p>All of this comes as the S&amp;P 500 and Nasdaq continue to grind outnew all-time highs.</p>\n<p>It also comes as FAANG stocks continue to trade incredibly well. Alphabet&nbsp;(<b>GOOGL</b>) -Get Reportis the top performerwith a near-40% gain in the first half of the year, while Netflix&nbsp;(<b>NFLX</b>) -Get Report&nbsp;is the worst, with a 2.3% drop.</p>\n<p>Alibaba has a similar first-half performance, down 2.6%. However, it’s doing far worse from the highs, down more than 30%.</p>\n<p>Can it turn around its woes in the second half and start rallying higher?</p>\n<p><img src=\"https://static.tigerbbs.com/9975f383919ff8cfc34fca49a32d8e8f\" tg-width=\"700\" tg-height=\"494\"></p>\n<p>Call me a hopeless optimist, but I feel that Alibaba can have a solid second-half performance.</p>\n<p>The overall market has done too well and so has large-cap tech. The fundamentals of the business are intact and growth is strong. It’s like Amazon&nbsp;(<b>AMZN</b>) -Get Report.Eventually, it will perform better&nbsp;- it’s a question of “when” and not “if.”</p>\n<p>Shares continue to hold the $210 to $212 area and have recently cleared downtrend resistance (blue line). That said, there’s plenty of overhead hurdles.</p>\n<p>Specifically, Alibaba stock is struggling with the 21-week moving average, as well as the 21-month and 10-month moving averages.</p>\n<p>Let’s be clear: There are not a lot of bullish technical components here. If Alibaba stock could hold the 10-week moving average on this week’s dip, I’d feel better about it.</p>\n<p>However, as long as it can hold up over the $210 level and really, the 200-week moving average, I feel okay about Alibaba going into the next six months.</p>\n<p>A push over $235 - thus putting it over all of the moving average hurdles mentioned above - could open up a run to $250, then $263. Above $275 and $300 is in play.</p>\n<p>Keep the risk in mind but this could be a solid second-half rebound play.</p>","source":"lsy1610613172068","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Can Alibaba Turn Around Its Woes in the Second Half of 2021?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCan Alibaba Turn Around Its Woes in the Second Half of 2021?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-03 10:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/alibaba-baba-stock-second-half-2021-trading?puc=yahoo&cm_ven=YAHOO><strong>The Street</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alibaba has been a sore laggard compared with its large- and mega-cap peers. Can that change in the second half of 2021?\n\nAlibaba (BABA) -Get Report has been a total dog so far this year. Shares were ...</p>\n\n<a href=\"https://www.thestreet.com/investing/alibaba-baba-stock-second-half-2021-trading?puc=yahoo&cm_ven=YAHOO\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BABA":"阿里巴巴","09618":"京东集团-SW"},"source_url":"https://www.thestreet.com/investing/alibaba-baba-stock-second-half-2021-trading?puc=yahoo&cm_ven=YAHOO","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146176335","content_text":"Alibaba has been a sore laggard compared with its large- and mega-cap peers. Can that change in the second half of 2021?\n\nAlibaba (BABA) -Get Report has been a total dog so far this year. Shares were trading well into the fourth quarter of 2020 but then a string of issues pummeled the stock.\nRegulators disrupted Ant's initial public offering, then dug deeper on Alibaba and dialed up the heat.\nInvestors don’t like regulatory issues as it is but particularly when we’re dealing with Chinese regulators.\nHowever, in April, Alibaba paid a smaller-than-expectedbut still record fine, hoping to puts its regulatory issues behind it. Still, the stock hasn’t responded the way bulls were hoping.\nAll of this comes as the S&P 500 and Nasdaq continue to grind outnew all-time highs.\nIt also comes as FAANG stocks continue to trade incredibly well. Alphabet (GOOGL) -Get Reportis the top performerwith a near-40% gain in the first half of the year, while Netflix (NFLX) -Get Report is the worst, with a 2.3% drop.\nAlibaba has a similar first-half performance, down 2.6%. However, it’s doing far worse from the highs, down more than 30%.\nCan it turn around its woes in the second half and start rallying higher?\n\nCall me a hopeless optimist, but I feel that Alibaba can have a solid second-half performance.\nThe overall market has done too well and so has large-cap tech. The fundamentals of the business are intact and growth is strong. It’s like Amazon (AMZN) -Get Report.Eventually, it will perform better - it’s a question of “when” and not “if.”\nShares continue to hold the $210 to $212 area and have recently cleared downtrend resistance (blue line). That said, there’s plenty of overhead hurdles.\nSpecifically, Alibaba stock is struggling with the 21-week moving average, as well as the 21-month and 10-month moving averages.\nLet’s be clear: There are not a lot of bullish technical components here. If Alibaba stock could hold the 10-week moving average on this week’s dip, I’d feel better about it.\nHowever, as long as it can hold up over the $210 level and really, the 200-week moving average, I feel okay about Alibaba going into the next six months.\nA push over $235 - thus putting it over all of the moving average hurdles mentioned above - could open up a run to $250, then $263. Above $275 and $300 is in play.\nKeep the risk in mind but this could be a solid second-half rebound play.","news_type":1,"symbols_score_info":{"09618":0.9,"BABA":0.9}},"isVote":1,"tweetType":1,"viewCount":2821,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":152368056,"gmtCreate":1625271119175,"gmtModify":1703739623563,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/152368056","repostId":"2148870441","repostType":4,"isVote":1,"tweetType":1,"viewCount":405,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":839666050,"gmtCreate":1629157226470,"gmtModify":1676529946229,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/839666050","repostId":"2160538227","repostType":4,"isVote":1,"tweetType":1,"viewCount":1525,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":803100979,"gmtCreate":1627426376491,"gmtModify":1703489536591,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/803100979","repostId":"1170349743","repostType":4,"isVote":1,"tweetType":1,"viewCount":1967,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":176849810,"gmtCreate":1626877335530,"gmtModify":1703479814474,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/176849810","repostId":"2153610465","repostType":4,"isVote":1,"tweetType":1,"viewCount":1690,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":154334836,"gmtCreate":1625478175925,"gmtModify":1703742420400,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/154334836","repostId":"1111176344","repostType":4,"repost":{"id":"1111176344","kind":"news","pubTimestamp":1625463785,"share":"https://ttm.financial/m/news/1111176344?lang=en_US&edition=fundamental","pubTime":"2021-07-05 13:43","market":"us","language":"en","title":"Neurodegenerative Disease, Cancer Stocks Among Top Biotech Gainers In 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=1111176344","media":"Benzinga","summary":"Biotech stocks underperformed the broader market in the first half of 2021, with the iShares Nasdaq ","content":"<div>\n<p>Biotech stocks underperformed the broader market in the first half of 2021, with the iShares Nasdaq Biotechnology ETF advancing about 8% year-to-date compared to the roughly 14% gain for the S&P 500 ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/07/21773695/neurodegenerative-disease-cancer-stocks-among-top-biotech-gainers-in-2021\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neurodegenerative Disease, Cancer Stocks Among Top Biotech Gainers In 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurodegenerative Disease, Cancer Stocks Among Top Biotech Gainers In 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-05 13:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/07/21773695/neurodegenerative-disease-cancer-stocks-among-top-biotech-gainers-in-2021><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biotech stocks underperformed the broader market in the first half of 2021, with the iShares Nasdaq Biotechnology ETF advancing about 8% year-to-date compared to the roughly 14% gain for the S&P 500 ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/07/21773695/neurodegenerative-disease-cancer-stocks-among-top-biotech-gainers-in-2021\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PDSB":"PDS Biotechnology Corporation","ENTX":"Entera Bio Ltd.","SAVA":"Cassava Sciences Inc","ATOS":"Atossa Genetics Inc","AVXL":"Anavex Life Sciences Corp.","BTX":"BlackRock Technology and Private Equity Term Trust","MRK":"默沙东","ANVS":"Annovis Bio, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/07/21773695/neurodegenerative-disease-cancer-stocks-among-top-biotech-gainers-in-2021","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111176344","content_text":"Biotech stocks underperformed the broader market in the first half of 2021, with the iShares Nasdaq Biotechnology ETF advancing about 8% year-to-date compared to the roughly 14% gain for the S&P 500 Index.\nIn comparison, the IBB was up 13.6% in the first half of 2020. The strength in the space in the last year was primarily due to risk aversion as the pandemic drove investors into defensive plays such as biotechs. Additionally, companies that kickstarted COVID-19 vaccine programs ran up sharply in 2020.\nThe relatively muted performance so far this year may have to do with the return of risk appetite leading to rotation out of the sector. The rally in vaccine stocks also moderated following emergency use authorizations being accorded for three COVID-19 shots.\nHere are a few stocks that stood out with solid gains amid the muted overall sector performance:\nCassava Sciences Inc : Shares of Cassava, a neurodegenerative disease company, spiked in early February on the back of positive results from the interim analysis of data from an open-label study of simufilam, its lead drug candidate for the treatment of Alzheimer's disease.\nIt hit an intraday high of $117.54 on Feb. 4. After pulling back and consolidating, the stock picked up pace in June. By virtue of the strong advance in the year-to-date period, the stock has tacked on about 1,150%.\nAnnovis Bio Inc : This biopharma that focuses on therapies for neurodegenerative diseases has seen its shares surge by over 1, 060% so far this year.\nThe company's lead drug ANVS401 is being evaluated for multiple indications, including Alzheimer's disease and Parkinson's disease. It works by improving axonal transport by inhibiting the neurotoxic proteins that kill nerve cells. A positive Phase 2 readout for the asset in Alzheimer's disease sent the stock soaring in late April.\nAtossa Therapeutics Inc : The Seattle-based biopharma focusing on treatments for breast cancer and COVID-19 has surged up about 770% year-to-date.\nFrom under $1 at the start of year, the stock rallied to a high of $4.90 in early February on the back of positive Phase 2 data for Endoxifen administered between diagnosis and surgery in breast cancer patients. The upward momentum faltered subsequently and the stock pulled back to a low of $1.48 on April 19.\nAtossa recovered from there and the rally picked up steam in June amid the release of positive final Phase 2 data for Endoxifen and inclusion in the Russell 2000 and 3000 indexes.\nEntera Bio Ltd. : The biopharma, which develops orally delivered large molecule therapeutics for use in areas with significant unmet medical need, has seen its shares surge higher by over 460% so far this year.\nThe company's pipeline consists of EB613, which is being evaluated for osteoporosis, and EB612 for hypoparathyroidism.\nEntera Bio shares jumped in early April when it reported positive topline biomarker data for EB613. The stock received a shot in the arm from the positive six-month bone mineral density results from the Phase 2 clinical trial of EB613, which the company reportedlast week.\nPDS Biotechnology Corp : PDS has gained about 450% year-to-date. The company has oncology and infectious disease programs.\nThe gains for the year-to-date period reflected the presentation of data from the Phase 2 combination study with PDS0101 in HPV-associated tumors at the ASCO conference, and also its COVID-19 program.\nAnavex Life Sciences Corp. shares have gained about 430% year-to-date. The company is developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders.\nThe company's lead product candidate blarcamesine (ANAVEX2-73) is being evaluated for multiple indications. The predictive biomarker of response established with SIGMAR1 mRNA expression correlates significantly with responses in primary and secondary clinical efficacy endpoints from the proof-of-concept Phase 2 trial in Parkinson's disease, the company announced.\nBrooklyn ImmunoTherapeutics Inc : This New York-based gene and cell therapy company has clocked gains of about 375% year-to-date.\nThe company is focused on exploring the role cytokine-based therapy can have in treating patients with cancer. The company is also exploring opportunities to advance oncology, blood disorder and monogenic disease therapies using highly innovative gene editing/cell therapy technology.\nBrooklyn initiated a mid-stage study of IRX-2 in combination with Merck & Co., Inc.'s Keytruda and chemotherapy in triple-negative breast cancer.\nIn March, the company completed its reverse merger with NTN Buzztime.\nHoward Federoff took over as CEO in early April. Later that month, the company acquired an exclusive license for mRNA gene editing and cell therapies technology of Factor Bioscience and Novellus Therapeutics, pursuant to an exercise of a previously announced option.\nThe company has also been added to the Russell 3000 Index.\nBrooklyn's most advanced program is the study of the lead asset IRX-2, a human cell-derived biologic with multiple active cytokine components in patients with head and neck cancer. With commercialization years away — and ultimately contingent on IRX-2 clearing clinical and regulatory hurdles — the valuation of Brooklyn looks a little stretched.","news_type":1,"symbols_score_info":{"MRK":0.9,"SAVA":0.9,"BTX":0.9,"AVXL":0.9,"PDSB":0.9,"ATOS":0.9,"ANVS":0.9,"ENTX":0.9}},"isVote":1,"tweetType":1,"viewCount":2032,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":152366771,"gmtCreate":1625271209393,"gmtModify":1703739627310,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/152366771","repostId":"2148181808","repostType":4,"isVote":1,"tweetType":1,"viewCount":1596,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123501714,"gmtCreate":1624427620738,"gmtModify":1703836372839,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/123501714","repostId":"1174011543","repostType":4,"repost":{"id":"1174011543","kind":"news","pubTimestamp":1624425845,"share":"https://ttm.financial/m/news/1174011543?lang=en_US&edition=fundamental","pubTime":"2021-06-23 13:24","market":"us","language":"en","title":"FDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=1174011543","media":"WSJ","summary":"The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the obje","content":"<p>The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the objection of agency statisticians who said there was insufficient evidence to support approval, according to newly released internal memos.</p>\n<p>In the internal memos released Tuesday, FDA officials discussed whether to approve the drug fromBiogenInc.BIIB-1.71%over objections from the agency’s drug statistics office, which said that clinical trial data fell short of the proof typically required to put a new product on the market.</p>\n<p>Ultimately, top officials decided that the evidence indicating that the drug worked, while inconclusive, was strong enough to allow doctors and patients to decide for themselves whether to take it, according to the memos.</p>\n<p>“FDA, then, is faced with a situation where the available evidence on the clinical endpoints is short of what we would require for standard approval of aducanumab,” wrote Peter Stein, director of the FDA’s office of new drugs, in a memo detailing his support for approval. “At the same time, patients with [Alzheimer’s] have a serious, progressive, ultimately fatal disease and are desperate for treatments.”</p>\n<p>The FDA made public its internal deliberations as it faces criticism from some doctors and scientists over the June 7 approval of the drug, called Aduhelm.</p>\n<p>The critics say the FDA ignored the scientific standards it typically holds drugmakers to and could prompt the federal government to spend billions of dollars on a drug that may not work.</p>\n<p>“While I fully support the Center’s recent decision to approve the therapy, I acknowledge that there are different opinions about this decision, including within FDA, and there likely will continue to be questions around our process for review and the data we considered to support the approval,” said FDA Acting Commissioner Janet Woodcock. “In the end, an experienced group of medical reviewers at FDA concluded that there was sufficient evidence to approve the Alzheimer’s therapy via the accelerated approval pathway.”</p>\n<p>Supporters say the FDA decision provides a lifeline to patients who have lacked any medicine promising to slow the progression of Alzheimer’s, and that the decision couldspur the development of more, better medicines.</p>\n<p>The agency usually releases approval documents after a decision, though not typically as quickly as it did this time. The 83 pages of memos appear to be a portion of the FDA’s deliberations, largely reflecting the exchanges of top officials.</p>\n<p>Tristan Massie, a biostatistics reviewer for the FDA, “does not agree that the totality of the data provides sufficient evidence to support the efficacy of aducanumab in Alzheimer’s disease and does not recommend approval,” one of the internal documents shows.</p>\n<p>Patrizia Cavazzoni, the FDA’s top-ranking drug-evaluation official, wrote in another memo that the agency’s drug biostatistics office “provided documentation for its recommendation that substantial evidence of effectiveness had not been provided in the application.”</p>\n<p>That office’s full dissenting analysis wasn’t included in the materials made available Tuesday, but portions of it were.</p>\n<p>Despite the objections, Dr. Cavazzoni wrote that Biogen had met the requirements for an “accelerated approval,” a type of regulatory clearance that allows a drug to be marketed even when there remains uncertainty about its clinical benefit if it fills an unmet need for a serious disease and has effects against a biological sign of the disease.</p>\n<p>Dr. Cavazzoni wrote that Aduhelm met that standard because of its effect of reducing a sticky substance called amyloid which “is reasonably likely to predict clinical benefit.”</p>\n<p>Some doctors and scientists saytargeting the amyloid plaqueshasn’t been proven to slow Alzheimer’s. Some members of a panel of advisers that recommended the FDA reject the drug haveresigned from the committee, citing the agency’s approval.</p>\n<p>Biogen listed the price of Aduhelm at $56,000 a year, and patients and Medicare could also face testing charges.</p>\n<p>About six million Americans suffer from Alzheimer’s, a progressive condition that robs people of their memories and cognitive abilities. Biogen has said that as many as two million of them may benefit from the medicine.</p>\n<p>The FDA approval sent Biogen’s stock soaring. The company has said it expects only minimal revenue from the drug this year, in part because of the logistical challenges in administering the medicine, but that sales would begin to increase next year.</p>\n<p>Analysts estimate sales of $946.3 million in 2022, according to FactSet. Sales are seen growing to $5.2 billion in 2026.</p>\n<p>The memos show FDA officials attempting to balance the subpar study data for Aduhelm with the desire of Alzheimer’s patients and their families to try any new treatment that might help.</p>\n<p>“There remains residual uncertainty regarding clinical benefit,” Dr. Stein wrote. But if the FDA were to wait for the company to finish another clinical study, “any approval would occur after a multiple year delay” and patients “could suffer irreversible loss of brain neurons and cognitive function and memory,” he wrote.</p>\n<p>The FDA said it plans to release more documents regarding its decision making as early as next week.</p>\n<p>The FDA’s approval was based primarily on two large Phase 3 clinical trials launched by Biogen to prove its drug helped slow the cognitive decline of people with early-stage Alzheimer’s.</p>\n<p>In March 2019, the companyhalted the studies earlyafter an independent monitoring board concluded the drug was unlikely to help patients.</p>\n<p>Seven months later, however,the company made a surprising reversaland said it was now planning to seek FDA approval after conducting additional analyses of trial data that came in after the studies were halted. The company said its analyses found the drug was successful in one study but failed in the second.</p>\n<p>The FDA memos provide some new details on Biogen’s about-face. In June 2019, the company met with FDA officials and both sides agreed the studies shouldn’t have been stopped, according to a “summary memorandum” document.</p>\n<p>At the meeting, FDA officials recommended that Biogen analyze the studies further to understand if it was still possible to draw conclusions from the data, despite the halt of the trials and conflicting results.</p>\n<p>Several months later, in October 2019, the agency and company met again and agreed that the studies could still be used to evaluate the drug’s effectiveness, according to the memo.</p>\n<p>The following day, on Oct. 22, Biogen announcedit would seek approval for the medicine, sending up its share price and adding billions of dollars to its market value.</p>\n<p>The company had been quietly re-examining the data for months, but didn’t have the confidence to move forward until the latest meeting with FDA officials, Biogen Chief Executive Michel Vounatsos said in an interview at the time.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-23 13:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/fda-approved-biogen-alzheimers-drug-despite-some-staff-concerns-11624393800?mod=hp_lead_pos2><strong>WSJ</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the objection of agency statisticians who said there was insufficient evidence to support approval, ...</p>\n\n<a href=\"https://www.wsj.com/articles/fda-approved-biogen-alzheimers-drug-despite-some-staff-concerns-11624393800?mod=hp_lead_pos2\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.wsj.com/articles/fda-approved-biogen-alzheimers-drug-despite-some-staff-concerns-11624393800?mod=hp_lead_pos2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174011543","content_text":"The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the objection of agency statisticians who said there was insufficient evidence to support approval, according to newly released internal memos.\nIn the internal memos released Tuesday, FDA officials discussed whether to approve the drug fromBiogenInc.BIIB-1.71%over objections from the agency’s drug statistics office, which said that clinical trial data fell short of the proof typically required to put a new product on the market.\nUltimately, top officials decided that the evidence indicating that the drug worked, while inconclusive, was strong enough to allow doctors and patients to decide for themselves whether to take it, according to the memos.\n“FDA, then, is faced with a situation where the available evidence on the clinical endpoints is short of what we would require for standard approval of aducanumab,” wrote Peter Stein, director of the FDA’s office of new drugs, in a memo detailing his support for approval. “At the same time, patients with [Alzheimer’s] have a serious, progressive, ultimately fatal disease and are desperate for treatments.”\nThe FDA made public its internal deliberations as it faces criticism from some doctors and scientists over the June 7 approval of the drug, called Aduhelm.\nThe critics say the FDA ignored the scientific standards it typically holds drugmakers to and could prompt the federal government to spend billions of dollars on a drug that may not work.\n“While I fully support the Center’s recent decision to approve the therapy, I acknowledge that there are different opinions about this decision, including within FDA, and there likely will continue to be questions around our process for review and the data we considered to support the approval,” said FDA Acting Commissioner Janet Woodcock. “In the end, an experienced group of medical reviewers at FDA concluded that there was sufficient evidence to approve the Alzheimer’s therapy via the accelerated approval pathway.”\nSupporters say the FDA decision provides a lifeline to patients who have lacked any medicine promising to slow the progression of Alzheimer’s, and that the decision couldspur the development of more, better medicines.\nThe agency usually releases approval documents after a decision, though not typically as quickly as it did this time. The 83 pages of memos appear to be a portion of the FDA’s deliberations, largely reflecting the exchanges of top officials.\nTristan Massie, a biostatistics reviewer for the FDA, “does not agree that the totality of the data provides sufficient evidence to support the efficacy of aducanumab in Alzheimer’s disease and does not recommend approval,” one of the internal documents shows.\nPatrizia Cavazzoni, the FDA’s top-ranking drug-evaluation official, wrote in another memo that the agency’s drug biostatistics office “provided documentation for its recommendation that substantial evidence of effectiveness had not been provided in the application.”\nThat office’s full dissenting analysis wasn’t included in the materials made available Tuesday, but portions of it were.\nDespite the objections, Dr. Cavazzoni wrote that Biogen had met the requirements for an “accelerated approval,” a type of regulatory clearance that allows a drug to be marketed even when there remains uncertainty about its clinical benefit if it fills an unmet need for a serious disease and has effects against a biological sign of the disease.\nDr. Cavazzoni wrote that Aduhelm met that standard because of its effect of reducing a sticky substance called amyloid which “is reasonably likely to predict clinical benefit.”\nSome doctors and scientists saytargeting the amyloid plaqueshasn’t been proven to slow Alzheimer’s. Some members of a panel of advisers that recommended the FDA reject the drug haveresigned from the committee, citing the agency’s approval.\nBiogen listed the price of Aduhelm at $56,000 a year, and patients and Medicare could also face testing charges.\nAbout six million Americans suffer from Alzheimer’s, a progressive condition that robs people of their memories and cognitive abilities. Biogen has said that as many as two million of them may benefit from the medicine.\nThe FDA approval sent Biogen’s stock soaring. The company has said it expects only minimal revenue from the drug this year, in part because of the logistical challenges in administering the medicine, but that sales would begin to increase next year.\nAnalysts estimate sales of $946.3 million in 2022, according to FactSet. Sales are seen growing to $5.2 billion in 2026.\nThe memos show FDA officials attempting to balance the subpar study data for Aduhelm with the desire of Alzheimer’s patients and their families to try any new treatment that might help.\n“There remains residual uncertainty regarding clinical benefit,” Dr. Stein wrote. But if the FDA were to wait for the company to finish another clinical study, “any approval would occur after a multiple year delay” and patients “could suffer irreversible loss of brain neurons and cognitive function and memory,” he wrote.\nThe FDA said it plans to release more documents regarding its decision making as early as next week.\nThe FDA’s approval was based primarily on two large Phase 3 clinical trials launched by Biogen to prove its drug helped slow the cognitive decline of people with early-stage Alzheimer’s.\nIn March 2019, the companyhalted the studies earlyafter an independent monitoring board concluded the drug was unlikely to help patients.\nSeven months later, however,the company made a surprising reversaland said it was now planning to seek FDA approval after conducting additional analyses of trial data that came in after the studies were halted. The company said its analyses found the drug was successful in one study but failed in the second.\nThe FDA memos provide some new details on Biogen’s about-face. In June 2019, the company met with FDA officials and both sides agreed the studies shouldn’t have been stopped, according to a “summary memorandum” document.\nAt the meeting, FDA officials recommended that Biogen analyze the studies further to understand if it was still possible to draw conclusions from the data, despite the halt of the trials and conflicting results.\nSeveral months later, in October 2019, the agency and company met again and agreed that the studies could still be used to evaluate the drug’s effectiveness, according to the memo.\nThe following day, on Oct. 22, Biogen announcedit would seek approval for the medicine, sending up its share price and adding billions of dollars to its market value.\nThe company had been quietly re-examining the data for months, but didn’t have the confidence to move forward until the latest meeting with FDA officials, Biogen Chief Executive Michel Vounatsos said in an interview at the time.","news_type":1,"symbols_score_info":{"BIIB":0.9}},"isVote":1,"tweetType":1,"viewCount":300,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123506627,"gmtCreate":1624427703869,"gmtModify":1703836375456,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/123506627","repostId":"2145066250","repostType":4,"isVote":1,"tweetType":1,"viewCount":618,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}